Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma Meeting Abstract

  

Authors:	Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Portlock, C. S.; Straus, D. J.; Chen, A.; Little, R. F.; France, F.; Whang, J.; Mishra, N.; Jarjies, C.; Gerecitano, J. F.
Abstract Title:	Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma
Meeting Title:	57th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	126
Issue:	23
Meeting Dates:	2015 Dec 5-8
Meeting Location:	Orlando, FL
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2015-12-03
Language:	English
ACCESSION:	WOS:000368020102203
PROVIDER:	wos
DOI:	10.1182/blood.V126.23.2691.2691
Notes:	Meeting Abstract: 2691 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/91580